New data confirms Arcellx’s anito-cel is a powerful and safe CAR-T cell therapy for relapsed or refractory multiple myeloma, showing deep, durable responses.
Gilead’s Trodelvy did not significantly improve progression-free survival in a key late-stage study for common breast cancer, though early data hints at a possible survival benefit.
Biotech firm Galapagos winds down cell therapy business affecting 365 jobs across 5 countries after unsuccessful sale attempts. Stock drops 15% on announcement.
Gilead Sciences settled lawsuits with generic manufacturers, securing market exclusivity for Biktarvy until April 2036.
